Drug Trial Radar · NCT02952820
Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
Last checked: Nov 20, 2026Latest source record: Feb 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
971
Actual
Start
Nov 15, 2016
Primary completion
Jan 8, 2019
Study completion Jan 8, 2019
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Nov 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.
Conditions
- Insomnia Disorder
Interventions
lemborexantDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6Time frame: Baseline and Month 6
Locations
114 sites in 12 countries. Site status is shown where the registry gives one.
Facility # 1
Chandler, Arizona
Facility # 2
Chandler, Arizona
Facility # 1
Rogers, Arkansas
Facility # 1
Beverly Hills, California
Facility # 2
Los Angeles, California
Facility # 1
Los Angeles, California
Facility # 1
Redlands, California
Facility # 1
Sacramento, California
Facility # 1
Santa Monica, California
Facility # 1
Torrance, California
Facility # 1
Colorado Springs, Colorado
Facility # 1
Celebration, Florida
Facility # 1
Hialeah, Florida
Facility # 1
Homestead, Florida
Facility # 1
Jacksonville, Florida
Facility # 1
Lauderhill, Florida
Facility # 1
Maitland, Florida
Innovative Clinical Research Inc
Miami, Florida
Facility # 1
Ocala, Florida
Facility # 1
Orlando, Florida
Facility # 1
Oviedo, Florida
Facility # 1
Pinellas Park, Florida
Facility # 1
Tampa, Florida
Facility # 1
The Villages, Florida
Facility # 1
Evansville, Indiana
Facility # 1
Elkridge, Maryland
Facility # 1
Quincy, Massachusetts
Facility # 1
Kansas City, Missouri
Facility # 1
Albuquerque, New Mexico
Facility # 1
Brooklyn, New York
Facility # 1
Hickory, North Carolina
Facility # 1
Dayton, Ohio
Facility # 2
Oklahoma City, Oklahoma
Facility # 1
Oklahoma City, Oklahoma
Facility # 1
Portland, Oregon
Facility # 1
Lincoln, Rhode Island
Facility # 1
Memphis, Tennessee
Facility # 1
Austin, Texas
Facility # 2
Austin, Texas
Facility # 1
Fort Worth, Texas
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.